Wells Fargo lowered the firm’s price target on Abbott (ABT) to $142 from $147 and keeps an Overweight rating on the shares after the company reported about in-line Q2 sales and EPS. Abbott lowered 2025 organic sales growth guide due to transitory headwinds in Dx and narrowed its EPS guide. The firm believes the 2026 outlook is intact.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott upgraded to Buy from Hold at Jefferies
- Abbott Laboratories Reports Strong Q2 2025 Results
- Abbott’s Earnings Call: Strong Growth Amid Challenges
- Abbott Laboratories: Temporary Challenges Amid Strong Long-Term Growth Prospects Justify Buy Rating
- Abbott Laboratories: Strong Medical Devices Performance and Resilient Growth Amid Challenges